Germany’s strategic innovation unit and business incubator, Evonik Creavis, has opened a new satellite innovation facility in Cambridge, in the US state of Massachusetts.
The facility, named Satellite Innovation, includes both labs and offices. Initially, Satellite Innovation will focus on research and development (R&D) activities for healthcare innovations such as nucleic acid-based medicines.
Go deeper with GlobalData
The new facility will also accelerate Evonik’s venture capital activities in the life sciences sector in the region. The investments will be focused on drug delivery technologies, cell culture, tissue engineering, and medical implants.
Anil Saxena, head of the facility said, “With our new Innovation Satellite in Cambridge, we are extending an invitation for collaboration to the brilliant minds across this dynamic region.”
Ralph Marquardt, chief innovation officer of Evonik said, “Addressing the global challenges of our time requires the worldwide collaboration of competent partners, and we are looking forward to jointly developing innovative solutions. We are strengthening regional R&D in North America and Asia to benefit from innovative ideas outside of Europe and be closer to our customers in those regions,”
Creavis’ Cambridge Innovation Satellite adds to Evonik’s ongoing R&D expansion in the US. In March 2023, the company broke ground on a new $220m lipid innovation centre in Lafayette, Indiana. Furthermore, in September 2022, it opened a new innovation hub in Allentown, Pennsylvania.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHeadquartered in the German city of Essen, Evonik Industries AG has production plants in over 27 countries with around 33,000 employees globally.
